Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Mar 6, 2017 -- Company to Host Conference Call at 4:30 p.m. Eastern Time -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducibl...
Mar 1, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company will host a conference call on Monday, March ...
Feb 13, 2017 - Akebia Expands Pipeline and Leverages Expertise in HIF Biology with Access to Extensive Library of Compounds Addressing Multiple Therapeutic Areas - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innov...
Feb 3, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Of...
Dec 20, 2016 - Funds Vadadustat Global Phase 3 PRO2TECT and INNO2VATE Studies - - Committed Capital and Potential Milestone Payments Could Exceed $1 Billion - - Akebia and Otsuka Share Revenue and Commercialization Costs Equally - - Akebia to Host Conference Ca...
Dec 12, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that the Opposition Division (OD) of the European Patent ...
Dec 2, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the company granted a newly hired executive an option ...
Nov 9, 2016 -- Multiple Publications Highlight Vadadustat's Potential to Treat Renal Anemia and the Need for New Therapies for Chronic Kidney Disease -- -- Company Expands Leadership Team with Additional Expertise in HIF Biology and Clinical Development -- CAMBRIDGE, Mass.--(BUSINESS WIR...
Oct 31, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Of...
Oct 17, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), announced today that additional supportive data from the vadadustat development...
Page:
1
... NextLast
= add release to Briefcase